Welcome to our dedicated page for Third Harmonic Bio news (Ticker: THRD), a resource for investors and traders seeking the latest updates and insights on Third Harmonic Bio stock.
Third Harmonic Bio, Inc. (THRD) generated news primarily as a clinical-stage biopharmaceutical company focused on dermal, respiratory, and gastrointestinal inflammatory diseases driven by mast cells. Its disclosures describe a research and development strategy centered on novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that regulates mast cell function and survival. The company’s news flow highlighted progress and decisions around its lead KIT inhibitor programs and subsequent corporate actions.
Earlier news items focused on the clinical development of THB335, a titratable, oral small molecule inhibitor of KIT. Releases covered the design and progress of a Phase 1 single and multiple ascending dose trial in healthy volunteers, including safety, pharmacokinetics, and pharmacodynamic effects measured through reductions in serum tryptase, a biomarker of mast cell activation. Updates also addressed Phase 2 readiness activities in chronic spontaneous urticaria, including completion of clinical, toxicology, and manufacturing work to support a potential Phase 2 trial.
Financial and corporate updates formed another major category of news. Third Harmonic Bio reported quarterly and annual financial results, describing research and development spending trends, the shift away from its THB001 program, and what it characterized as a strong cash and cash equivalents position. The company also issued releases about participation in healthcare and investor conferences, where management discussed its development programs and strategic outlook.
Later news items document a significant strategic shift. Third Harmonic Bio announced a strategic review process to explore potential strategic transactions and business combinations, halted non-THB335 research activities, and implemented workforce reductions. Subsequent releases described the board’s approval of a Plan of Liquidation and Dissolution, stockholder approval of the plan, expected liquidation distributions to stockholders, and the initiation of a sale process for THB335 and related intellectual property.
For readers researching THRD, this news archive provides a record of Third Harmonic Bio’s clinical data disclosures, financial reporting, strategic reviews, and ultimately its decision to liquidate and dissolve, including the steps toward delisting and winding down operations.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, announced that its CEO, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 7:30 a.m. ET.
The event will be webcast live on the Third Harmonic Bio website, with a replay available for 90 days post-event.
The company focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases.
Third Harmonic Bio (Nasdaq: THRD) announced its Q1 2024 financial results and business updates. The U.S. FDA cleared its IND application for THB335, enabling a Phase 1 clinical trial focusing on chronic spontaneous urticaria. Results are expected in the first half of 2025. The company strengthened its leadership, appointing Christopher J. Dinsmore, Ph.D., as Chief Scientific Officer, Dennis Dean, Ph.D., as Chief Non-Clinical Development Officer, and promoting Jennifer Dittman to Chief Development Operations Officer. Financially, the company reported cash and equivalents of $262.8 million, decreased R&D expenses to $6.2 million, and G&A expenses to $5.1 million. Net loss decreased to $7.9 million from $9.1 million a year earlier.
FAQ
What is the current stock price of Third Harmonic Bio (THRD)?
What is the market cap of Third Harmonic Bio (THRD)?
